Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
<p><strong>Background</strong> Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients w...
Main Authors: | Staplin, N, Haynes, R, Herrington, W, Judge, P, Emberson, J, Preiss, D, Mayne, K, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Landray, M, Baigent, C, The EMPA-KIDNEY Collaborative Group |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2023
|
Similar Items
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024) -
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024) -
Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
by: Preiss, D, et al.
Published: (2022) -
Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023) -
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
by: Nangaku, M, et al.
Published: (2024)